Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02642419
Recruitment Status : Unknown
Verified December 2015 by Japan Cardiovascular Research Foundation.
Recruitment status was:  Recruiting
First Posted : December 30, 2015
Last Update Posted : December 30, 2015
Sponsor:
Information provided by (Responsible Party):
Japan Cardiovascular Research Foundation

Tracking Information
First Submitted Date  ICMJE October 21, 2015
First Posted Date  ICMJE December 30, 2015
Last Update Posted Date December 30, 2015
Study Start Date  ICMJE January 2015
Estimated Primary Completion Date December 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 26, 2015)
  • Composite endpoint of cardiovascular events [ Time Frame: mean duration: 2 years, maximum duration: 3 years ]
    stroke, non-CNS embolism, myocardial infarction, unstable angina pectoris requiring revascularizations or all-cause mortality
  • Major bleeding defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria [ Time Frame: mean duration: 2 years, maximum duration: 3 years ]
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: December 26, 2015)
  • Net adverse clinical and cerebral events (NACCE) [ Time Frame: mean duration: 2 years, maximum duration: 3 years ]
    composite of all-cause death, myocardial infarction, stroke and major bleeding.
  • Ischemic cardiovascular events and death [ Time Frame: mean duration: 2 years, maximum duration: 3 years ]
    • All-cause mortality
    • Cardiovascular death
    • non-cardiovascular death
    • Myocardial infarction
    • Unstable angina pectoris requiring revascularization
    • Ischemic stroke
    • Transient ischemic attack
    • non-CNS embolism (systemic embolism pulmonary embolism, deep vein thrombosis)
    • PCI/CABG
    • Stent thrombosis
    • Ischemic stroke and systemic embolism
  • All bleeding events [ Time Frame: mean duration: 2 years, maximum duration: 3 years ]
  • Adverse events excluding hemorrhagic events [ Time Frame: mean duration: 2 years, maximum duration: 3 years ]
  • Comparison of the primary endpoints, ischemic cardiovascular events and mortality between patients treated with aspirin and patients treated with thienopyridine derivatives [ Time Frame: mean duration: 2 years, maximum duration: 3 years ]
  • Subgroup analysis of primary endpoints, ischemic cardiovascular events and mortality according to the CHADS2 score and CHA2DS2-VASc score [ Time Frame: mean duration: 2 years, maximum duration: 3 years ]
  • Subgroup analysis of primary endpoints, ischemic cardiovascular events and mortality according to subject characteristics [ Time Frame: mean duration: 2 years, maximum duration: 3 years ]
  • Subgroup analysis of major bleeding and all bleeding events according to the HAS-BLED score in patients with and without co-administration of antiplatelet drug and analysis of specificity and sensitivity [ Time Frame: mean duration: 2 years, maximum duration: 3 years ]
  • Comparison of the incidence of bleeding events according to whether or not proton pump inhibitors (PPIs) are used [ Time Frame: mean duration: 2 years, maximum duration: 3 years ]
  • Comparison of the incidence of the primary endpoints according to whether rivaroxaban is administered in the morning or evening [ Time Frame: mean duration: 2 years, maximum duration: 3 years ]
    Primary endpoints include the composite endpoint of cardiovascular events (stroke, non-CNS embolism, myocardial infarction, unstable angina pectoris requiring revascularization or cardiovascular death) and major bleeding defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria.
  • Correlation of discontinuation of antithrombotic agents with ischemic cardiovascular events, bleeding events and adverse events [ Time Frame: mean duration: 2 years, maximum duration: 3 years ]
  • Correlation of prothrombin time at trough with bleeding events and evaluation of the cutoff values in patients with and without co-administration of antiplatelet drug [ Time Frame: mean duration: 2 years, maximum duration: 3 years ]
  • The incidence of the primary endpoints according to different rates of adherence [ Time Frame: mean duration: 2 years, maximum duration: 3 years ]
    Primary endpoints include the composite endpoint of cardiovascular events (stroke, non-CNS embolism, myocardial infarction, unstable angina pectoris requiring revascularization or cardiovascular death) and major bleeding defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria. The rate of adherence will be calculated by dividing the number of prescribed tablets by the period of treatment: e.g., if 240 tablets are prescribed for 300 days, the rate of adherence will be 80.0% (240/300).
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study
Official Title  ICMJE Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study)
Brief Summary

In patients with atrial fibrillation (AF) complicated with coronary artery disease (CAD), antiplatelet drugs are commonly used for the prevention of recurrence of stent thrombosis and cardiovascular events in combination with anticoagulant drugs. Based on the observations that the incidence of hemorrhagic complications increased when an antiplatelet drug was administered in combination with vitamin K antagonist (VKA), the guidelines for antithrombotic therapy after PCI in the US and EU recommend that DAPT (dual anti-platelets therapy) should be used in AF-complicated CAD patients for as short a time as possible following single anti-platelet and VKA, and that monotherapy with VKA should be started from one year after PCI. In 2013 the European Heart Rhythm Association (EHRA) published the guidelines for the use of NOACs in NVAF patients, which state that NOACs may have advantage to VKAs in terms of anti-thrombotic effects in NVAF patients undergoing PCI. However, no clinical evidence has ever been generated to reveal the efficacy and safety of mono-drug therapy with a NOACs in stable CAD patients one year or more after PCI.

AFIRE study is planned to evaluate the efficacy and safety of mono-drug therapy with a rivaroxaban in stable CAD patients. Among NOACs, rivaroxaban was chosen because of the evidence in Japanese patients and the results of a sub-analysis of ROCKET AF suggesting that rivaroxaban is more effective than VKA in reducing the incidence of myocardial infarction (MI).

Detailed Description

Study Design:prospective, randomized, open-label trial

Allocation:ratio to rivaroxaban monotherapy and rivaroxaban in co-administration with a single anti-platelet therapy is 1: 1 using WEB system

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Atrial Fibrillation
Intervention  ICMJE
  • Drug: Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel)
    • Rivaroxaban will be orally administered after a meal at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min (regardless of time)
    • Antiplatelet will be selected from aspirin or thienopyridine derivatives (clopidogrel or prasugrel)

      • Aspirin will be orally administered once a day at a dose of 81 mg or 100 mg
      • Clopidogrel will be orally administered once a day after a meal at a dose of 75 mg. The dose will be reduced to 50mg once a day depending on age, body weight or clinical findings.
      • Prasugrel will be orally administered once a day at a dose of 3.75 mg. If the body weight is 50kg or less a reduced dose(2.5 mg once a day) will be considered depending on the age, renal function or other bleeding and thrombotic risk.
  • Drug: Rivaroxaban
    Rivaroxaban will be orally administered at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min.
Study Arms  ICMJE
  • Experimental: Rivaroxaban
    Intervention: Drug: Rivaroxaban
  • Experimental: Rivaroxaban and single antiplatelet drug
    Intervention: Drug: Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel)
Publications * Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med. 2019 Sep 19;381(12):1103-1113. doi: 10.1056/NEJMoa1904143. Epub 2019 Sep 2.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: December 26, 2015)
2200
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2017
Estimated Primary Completion Date December 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Patients with non-valvular atrial fibrillation complicated with stable coronary artery disease who are 20 years or older, with CHADS2 score are ≧1 , and that fulfill one of the following criteria and can provide written consent for participation in the present study will be eligible.

  1. Patients who underwent percutaneous coronary intervention(PCI), including plain old balloon angioplasty(POBA), at least one year ago
  2. Patients who have coronary stenosis requiring no percutaneous coronary intervention (50% or more stenosis) as indicated by coronary CT or coronary angiography(CAG)
  3. Patients who underwent coronary artery bypass graft (CABG) at least one year ago

Exclusion Criteria:

  • Patients for whom rivaroxaban is contraindicated
  • Patients for whom aspirin, thienopyridine derivatives (clopidogrel or prasugrel) are contraindicated
  • Patients who underwent PCI, including POBA, in the past one year
  • Patients who are going to undergo revascularization
  • Patients who have a past history of stent thrombosis
  • Those who are going to undergo invasive surgery (excluding digestive endoscopy and biopsy)
  • Patients who have active tumors
  • Patients who have poorly-controlled hypertension (systolic blood pressure at hospital admission: 160 mmHg or more)
  • Patients who cannot discontinue treatment with antiplatelet drugs (the physician in charge will make a decision on the basis of the lesion shape, lesion site and type of stents.)
  • Patients judged as inappropriate for this study by investigators
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 20 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Japan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02642419
Other Study ID Numbers  ICMJE AFIRE Study
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Japan Cardiovascular Research Foundation
Study Sponsor  ICMJE Japan Cardiovascular Research Foundation
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Hisao Ogawa Japan Cardiovascular Research Foundation
PRS Account Japan Cardiovascular Research Foundation
Verification Date December 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP